D. E. Shaw & Co., Inc. Sellas Life Sciences Group, Inc. Put Options Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding SLS
# of Institutions
35Shares Held
8.03MCall Options Held
2.52MPut Options Held
24.7K-
Anson Funds Management LP Dallas, TX4.83MShares$5.51 Million0.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$1.73 Million0.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$351,6513.71% of portfolio
-
Black Rock Inc. New York, NY278KShares$317,1680.0% of portfolio
-
Geode Capital Management, LLC Boston, MA273KShares$311,2910.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $23.4M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...